Below, we list all observational studies identified
| Title | Study reference | Full text |
|---|---|---|
| Treatment with ACE-inhibitors is associated with less severe disease with SARS-Covid-19 infection in a multi-site UK acute Hospital Trust | Bean D, medRxiv, 2020 | Full text |
| Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial | Bian H, MedRxiv, 2020 | Full text |
| First Clinical Study Using HCV Protease Inhibitor Danoprevir to Treat Naive and Experienced COVID-19 Patients | Chen H, medRxiv, 2020 | Full text |
| Key to successful treatment of COVID-19: accurate identification of severe risks and early intervention of disease progression | Chen M, medRxiv, 2020 | Full text |
| The QT Interval in Patients with SARS-CoV-2 Infection Treated with Hydroxychloroquine/Azithromycin | Chorin E, medRxiv, 2020 | Full text |
| Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study | Deng L, J Infect, 2020 | Full text |
| Effectiveness of convalescent plasma therapy in severe COVID-19 patients | Duan K, Proc Natl Acad Sci USA, 2020 | Full text |
| Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial | Feng Z, medRxiv, 2020 | Full text |
| Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial | Gautret P, Int J Antimicrob Agents, 2020 | Full text |
| Compassionate Use of Remdesivir for Patients with Severe Covid-18 | Gautret P, Travel Med Infect Dis, 2020 | Full text |
| Compassionate Use of Remdesivir for Patients with Severe Covid-19 | Grein J, N Eng J Med, 2020 | Full text |
| Use of siltuximab in patients with COVID-19 pneumonia requiring ventilatory support | Gritti G, medRxiv, 2020 | Full text |
| Risk Factors Associated with Clinical Outcomes in 323 COVID-19 Patients in Wuhan, China | Hu L, medRxiv, 2020 | Full text |
| Impact of Corticosteroid Treatment in Patients with Coronavirus | Lei Z, Med J Aust, 2020 | Full text |
| Disease 2019 | Leng Z, Aging Dis, 2020 | Full text |
| Patients of COVID-19 may benefit from sustained Lopinavir-combined regimen and the increase of Eosinophil may predict the outcome of COVID-19 progression | Liu F, Int J Infect Dise, 2020 | Full text |
| Tocilizumab treatment in COVID-19: a single center experience | Luo P, J Med Virol, 2020 | Full text |
| An experimental trial of recombinant human interferon alpha nasal drops to prevent coronavirus disease 2019 in medical staff in an epidemic area | Meng Z, medRxiv, 2020 | Full text |
| No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection | Molina JM, Med Mal Infect, 2020 | Full text |
| Heparin therapy improving hypoxia in COVID-19 patients - a case series | Negri EM, medRxiv, 2020 | Full text |
| Experience with Hydroxychloroquine and Azithromycin in the COVID-19 Pandemic: Implications for QT Interval Monitoring | Ramireddy A, medRxiv, 2020 | Full text |
| Evaluation of Antiviral Therapies for Coronavirus Disease 2019 (COVID-19) Pneumonia in Shanghai, China | Shi X, J Med Virol, 2020 | Full text |
| Clinical observations of low molecular weight heparin in relieving inflammation in COVID-19 patients: A retrospective cohort study | Shi, medRxiv, 2020 | Full text |
| No Clear Benefit to the Use of Corticosteroid as Treatment in Adult Patients with Coronavirus Disease 2019 : A Retrospective Cohort Study | Wang D, medRxiv, 2020 | Full text |
| Early, low-dose and short-term application of corticosteroid treatment in patients with severe COVID-19 pneumonia: single-center experience from Wuhan, China | Wang Y, MedRxiv, 2020 | Full text |
| Plasminogen improves lung lesions and hypoxemia in patients with COVID-19 | Wu Y, Int J Med, 2020 | Full text |
| Adjuvant corticosteroid therapy for critically ill patients with COVID-19 | Xiaofan L, medRxiv, 2020 | Full text |
| Effective Treatment of Severe COVID-19 Patients with Tocilizumab | Xu X, ChinaXiv, 2020 | Full text |
| Factors associated with prolonged viral shedding and impact of Lopinavir/Ritonavir treatment in patients with SARS-CoV-2 infection | Yan D, medRxiv, 2020 | Full text |
| Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease 2018 | Ye X-T, Eur Rev Med Pharmacol Sci, 2020 | Full text |
| Potential of Arbidol for Post-exposure Prophylaxis of COVID-19 Transmission | Zhang J, chinaXiv, 2020 | Full text |
| Risk-adapted Treatment Strategy For COVID-19 Patients | Zheng Ch, Int J Inf Dis, 2020 | Full text |
| Interferon-a2b treatment for COVID-19 | Zhou Q, medRxiv, 2020 | Full text |
| Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia | Zhou W, Signal Transduct Target Ther, 2020 | Full text |
| Arbidol Monotherapy is Superior to Lopinavir/ritonavir in Treating COVID-19 | Zhu Z, J infect, 2020 | Full text |
| Effect of regular intravenous immunoglobulin therapy on prognosis of severe pneumonia in patients with COVID-19 | Zie Y, J Infect, 2020 | Full text |
| Exosomes Derived From Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19 | Sengupta V, Stem cells and developmen, 2020 | Full text |
| Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. | Cai Q, Engineering, 2020 | Full text |
| Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in severe patients with COVID-19. | Sciascia S, Clinical and experimental rheumatology, 2020 | Full text |
| Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19). | Mercuro N, JAMA cardiology, 2020 | Full text |
| Tocilizumab for the Treatment of Severe COVID-19 | Rand A, Journal of medical virology, 2020 | Full text |
| Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy | ToniatI P, Autoimmunity reviews , 2020 | Full text |
| Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: A retrospective study. | Lian N, Clinical microbiology and infection, 2020 | Full text |
| Full-length title: Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France. | Million M, Médecine des voyages et maladies infectieuses, 2020 | Full text |
| Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients | Klopfenstein T, Medecine et maladies infectieuses, 2020 | Full text |
| Tocilizumab for Treatment of Severe COVID-19 Patients: Preliminary Results from SMAtteo COvid19 REgistry (SMACORE) | Colaneri M, Microorganisms, 2020 | Full text |
| Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: Clinical outcome and differences in post_treatment hospitalisation status. | Antinori S, Basic research in cardiology, 2020 | Full text |
| Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia. | Capra R, European journal of internal medicine, 2020 | Full text |
| Hydroxychloroquine and azithromycin plus zinc vs hydroxychloroquine and azithromycin alone: outcomes in hospitalized COVID-19 patients | Carlucci P, medRxiv, 2020 | Full text |
| Treatment Response to Hydroxychloroquine, Lopinavir/Ritonavir, and Antibiotics for Moderate COVID 19: A First Report on the Pharmacological Outcomes from South Korea | Kim M, medRxiv, 2020 | Full text |
| Arbidol/IFN-?2b Therapy for Patients With Corona Virus Disease 2019: A Retrospective Multicenter Cohort Study | Xu P, Microbes and infection, 2020 | Full text |
| Effects of methylprednisolone use on viral genomic nucleic acid negative conversion and CT imaging lesion absorption in COVID-19 patients under 50 years old | Gong y, Journal of medical virology, 2020 | Full text |
| Rescue Therapy for Severe COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS) with Tissue Plasminogen Activator (tPA): A Case Series. | Barrett C, The journal of trauma and acute care surgery, 2020 | Full text |
| Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. | Zhu F, Lancet, 2020 | Full text |
| Acetic acid disinfection as a potential adjunctive therapy for non-severe COVID-19. | Pianta L, European archives of oto-rhino-laryngology, 2020 | Full text |
| Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in Milan, Italy. | Morena V, European journal of internal medicine, 2020 | Full text |
| Impact of anticoagulation prior to COVID-19 infection: a propensity score-matched cohort study. | Tremblay D, Blood, 2020 | Full text |
| Treatment of COVID-19 Patients with Convalescent Plasma. | Salazar E, The American journal of pathology, 2020 | Full text |
| Potential of Arbidol for Post-exposure Prophylaxis of COVID-19 Transmission-A Preliminary Report of a Retrospective Cohort Study. | Zhang J, Current medical science, 2020 | Full text |
| Hydroxychloroquine and azithromycin as a treatment of COVID-19. | Fanin A, Internal and emergency medicine, 2020 | Full text |
| Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study | Campochiaro C, European journal of internal medicine, 2020 | Full text |
| Efficacy and Safety of Leflunomide for Refractory COVID-19: An Open-label Controlled Study | Wang Q, medRxiv, 2020 | Full text |
| A cohort study to evaluate the effect of combination Vitamin D, Magnesium and Vitamin B12 (DMB) on progression to severe outcome in older COVID-19 patients. | Tan C W, medRxiv, 2020 | Full text |
| Treatment with Arbidol and Moxifloxacin in Ordinary and Severe Adult Patients Infected with COVID-19 | Yu D, , 2020 | Full text |
| Tocilizumab for patients with COVID-19 pneumonia. The TOCIVID-19 phase 2 trial | Perrone F, medRxiv, 2020 | Full text |
| Ozone therapy for patients with SARS-COV-2 pneumonia: a single-center prospective cohort study | HERNANDEZ A, medRxiv, 2020 | Full text |
| Therapeutic effectiveness of interferon-alpha2b against COVID-19: the Cuban experience | Pereda R, medRxiv, 2020 | Full text |
| [Clinical efficacy of Matrine and Sodium Chloride Injection in treatment of 40 cases of COVID-19]. | Yang M, Zhongguo Zhong yao za zhi, 2020 | Full text |
| Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. | Cavalli G, Lancet Rheumatology, 2020 | Full text |
| A study on clinical effect of Arbidol combined with adjuvant therapy on COVID-19. | Chen W, Journal of medical virology, 2020 | Full text |
| Lopinavir/ritonavir and interferon combination therapy may help shorten the duration of viral shedding in patients with COVID-19: a retrospective study in two designated hospitals in Anhui, China. | Zuo Y, Journal of medical virology, 2020 | Full text |
| Treatment of COVID-19 Patients with Convalescent Plasma in Houston, Texas. | Salazar E, medRxiv, 2020 | Full text |
| [Clinical study of artesunate in the treatment of coronavirus disease 2019]. | Lin Y, Zhonghua wei zhong bing ji jiu yi xue, 2020 | Full text |
| Lopinavir/ritonavir as a third agent in the antiviral regimen for SARS-CoV-2 infection. | Panagopoulos P, Zhonghua wei zhong bing ji jiu yi xue, 2020 | Full text |
| Subcutaneous administration of interferon beta-1a for COVID-19: A non-controlled prospective trial. | Dastan F, International immunopharmacology, 2020 | Full text |
| The comparison of the effectiveness of lincocin ® and azitro ® in the treatment of covid-19-associated pneumonia: A prospective study. | Guvenmez O, Journal of population therapeutics and clinical pharmacology, 2020 | Full text |
| Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019. | Kim JW, The Korean journal of internal medicine, 2020 | Full text |
| Tocilizumab is associated with reduction of the risk of ICU admission and mortality in patients with SARS-CoV-2 infection | Moreno Garcia E, medRxiv, 2020 | Full text |
| ICON (Ivermectin in COvid Nineteen) study: Use of Ivermectin is Associated with Lower Mortality in Hospitalized Patients with COVID19 | Rajter JC, medRxiv, 2021 | Full text |
| Prolonged SARS-CoV-2 Viral Shedding in Patients with COVID-19 was Associated with Delayed Initiation of Arbidol Treatment: a retrospective cohort study | Zhou Y, medRxiv, 2022 | Full text |
| Early administration of lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of SARS-CoV-2 infection: a retrospective cohort study. | Moreno Garcia E, medRxiv, 2023 | Full text |
| First Clinical Use of Lenzilumab to Neutralize GM-CSF in Patients with Severe and Critical COVID-19 Pneumonia | Temesgen Z, medRxiv, 2024 | Full text |
| Pre exposure Hydroxychloroquine use is associated with reduced COVID19 risk in healthcare workers | Bhattacharya Z, medRxiv, 2025 | Full text |
| A short therapeutic regimen based on hydroxychloroquine plus azithromycin for the treatment of COVID-19 in patients with non-severe disease. A strategy associated with a reduction in hospital admissions and complications. | Oteo JA, medRxiv, 2027 | Full text |
| Compassionate Use of Tocilizumab in Severe SARS-CoV2 Pneumonia. When late administration is too late. | Gorgolas M, medRxiv, 2029 | Full text |
| Hospitalized COVID-19 patients treated with Convalescent Plasma in a mid-size city in the midwest | Hartman W, medRxiv, 2020 | Full text |
| Compassionate Use of Opaganib For Patients with Severe COVID-19 | Kurd R, medRxiv, 2020 | Full text |
| Hydroxychloroquine serum concentrations in non-critical care patients infected with SARS CoV 2 | MacGowan A P, medRxiv, 2020 | Full text |
| Does Biological Therapy Protect against Severe COVID-19? | Mazzucchelli R, medRxiv, 2020 | Full text |
| Compassionate use of hydroxychloroquine in clinical practice for patients with mild to severe Covid-19 in a French university hospital. | Paccoud O ,Clinical infectious diseases, 2020 | Full text |
| Tocilizumab treatment for Cytokine Release Syndrome in hospitalized COVID-19 patients: survival and clinical outcomes. | Price C, CHEST, 2020 | Full text |
| The clinical value of two combination regimens in the Management of Patients Suffering from Covid-19 pneumonia: a single centered, retrospective, observational study. | Vahedi E, Daru, 2020 | Full text |
| Outcomes in Patients with Severe COVID-19 Disease Treated with Tocilizumab - A Case-?Controlled Study | Rojas-Marte, QJM, 2020 | Full text |
| Compassionate Use of Tocilizumab for Treatment of SARS-CoV-2 Pneumonia. | Jordan S, Clinical infectious diseases, 2020 | Full text |
| Effectiveness of Arbidol for COVID-19 Prevention in Health Professionals. | Yang C, Frontiers in public health, 2020 | Full text |
| Improved Clinical Symptoms and Mortality on Severe/Critical COVID-19 Patients Utilizing Convalescent Plasma Transfusion. | Xia X, Blood, 2020 | Full text |
| Repurposing chlorpromazine to treat COVID-19: The reCoVery study. | Plaze M, L'Encephale, 2020 | Full text |
| Therapeutic Plasma Exchange in Adults with Severe COVID-19 Infection. | Khamis F, International journal of infectious diseases, 2020 | Full text |
| Combination of Ruxolitinib and Eculizumab for Treatment of Severe SARS-CoV-2-Related Acute Respiratory Distress Syndrome: A Controlled Study. | Giudice V, Frontiers in pharmacology, 2020 | Full text |
| Critically ill patients with COVID-19 with ECMO and artificial liver plasma exchange: A retrospective study. | Liu J, Medicine, 2020 | Full text |
| First Clinical Use of Lenzilumab to Neutralize GM-CSF in Patients with Severe COVID-19 Pneumonia. | Temesgen Z, medRxiv, 2020 | Full text |
| Methylprednisolone added to tocilizumab reduces mortality in SARS-CoV-2 pneumonia: An observational study. | Sanz Herrero F, Journal of internal medicine, 2020 | Full text |
| Use of Anakinra to Prevent Mechanical Ventilation in Severe COVID-19: A Case Series. | Navarro-Millan I, Arthritis & rheumatology, 2020 | Full text |
| Use of Baricitinib in Patients with Moderate and Severe COVID-19. | Titanji B, Clinical infectious diseases, 2020 | Full text |
| Short-Term Dexamethasone in Sars-CoV-2 Patients. | Selvaraj V, medRxiv, 2020 | Full text |
| Tocilizumab and steroid treatment in patients with severe Covid-19 pneumonia. | Mikulska M, medRxiv, 2020 | Full text |
| Treatment of ARDS and hyperinflammation in COVID-19 with IL-6 antagonist Tocilizumab: a tertiary care experience from Pakistan | Nasir N, medRxiv, 2020 | Full text |
| Effects of Anticoagulants and Corticosteroids therapy in patients affected by severe COVID-19 Pneumonia | Sabir A M, medRxiv, 2020 | Full text |
| The therapeutic effectiveness of Convalescent plasma therapy on treating COVID-19 patients residing in respiratory care units in hospitals in Baghdad, Iraq | Rasheed A M, medRxiv, 2020 | Full text |
| Chronic treatment with hydroxychloroquine and SARS-CoV-2 infection. | Ferreira A, medRxiv, 2020 | Full text |
| A retrospective study evaluating efficacy and safety of compassionate use of tocilizumab in 13 patients with severe-to-critically ill COVID-19: analysis of well-responding cases and rapidly-worsening cases after tocilizumab administration | Hashimoto S, medRxiv, 2020 | Full text |
| Dual-Histamine Blockade with Cetirizine - Famotidine Reduces Pulmonary Symptoms in COVID-19 Patients | Hogan R, medRxiv, 2020 | Full text |
| Characteristics and outcomes of Acute Respiratory Distress Syndrome related to COVID-19 in Belgian and French Intensive Care Units according to antiviral strategies. The COVADIS multicenter observational study. | Grimaldi D, medRxiv, 2020 | Full text |
| Treatment Response to Hydroxychloroquine and Antibiotics for mild to moderate COVID-19: a retrospective cohort study from South Korea | An M. H., medRxiv, 2020 | Full text |
| Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management (Pilot Trial) | Gorial F. I., medRxiv, 2020 | Full text |
| Low-Dose Whole-Lung Radiation for COVID-19 Pneumonia | Hess C. B., medRxiv, 2020 | Full text |
| Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis. | Lagier JC, Travel medicine and infectious disease, 2020 | Full text |
| INFUSION OF CONVALESCENT PLASMA IS ASSOCIATED WITH CLINICAL IMPROVEMENT IN CRITICALLY ILL PATIENTS WITH COVID-19: A PILOT STUDY. | Olivares-Gazca JC, Revista de investigacion clinica, 2020 | Full text |
| Treatment with Hydroxychloroquine, Azithromycin, and Combination in Patients Hospitalized with COVID-19. | Arshad S, International journal of infectious diseases, 2020 | Full text |
| Lopinavir/ritonavir is associated with pneumonia resolution in COVID-19 patients with influenza coinfection: a retrospective matched-pair cohort study. | Yu C, Journal of medical virology, 2020 | Full text |
| Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study. | Della-Torre E, Annals of the rheumatic diseases, 2020 | Full text |
| Life-saving effect of convalescent plasma treatment in covid-19 disease: Clinical trial from eastern Anatolia. | Erkurt M A, Transfusion and apheresis science, 2020 | Full text |
| Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series. | Doi K, Critical care, 2020 | Full text |
| An Observational Cohort Study of Hydroxychloroquine and Azithromycin for COVID-19: (Can't Get No) Satisfaction. | Lee T, International journal of infectious diseases, 2020 | Full text |
| Tocilizumab in patients with severe COVID-19: A single-center observational analysis. | Knorr JP, Journal of medical virology, 2020 | Full text |
| Corticosteroid therapy for patients with CoVID-19 pneumonia: a before-after study. | Bani-Sadr F, International journal of antimicrobial agents, 2020 | Full text |
| Early use of tocilizumab in the prevention of adult respiratory failure in SARS-CoV-2 infections and the utilization of interleukin-6 levels in the management. | Suresh A, Journal of medical virology, 2020 | Full text |
| Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab. | Morrison A, Journal of autoimmunity, 2020 | Full text |
| Comparison of hydroxychloroquine, lopinavir/ritonavir, and standard of care in critically ill patients with SARS-CoV-2 pneumonia: an opportunistic retrospective analysis. | Lecronier M, Critical care, 2020 | Full text |
| Clinical and laboratory evaluation of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma: a prospective study | Donato, M, medRxiv, 2020 | Full text |
| COVIDOSE: Low-dose tocilizumab in the treatment of Covid-19 | Strohbehn, G. W, medRxiv, 2020 | Full text |
| Remdesivir for COVID-19: match-population analysis with compassionate use of Remdesivir for severe COVID-19 | Vasylyeva, O, medRxiv, 2020 | Full text |
| SECOND WEEK METHYL-PREDNISOLONE PULSES IMPROVE PROGNOSIS IN PATIENTS WITH SEVERE CORONAVIRUS DISEASE 2019 PNEUMONIA: AN OBSERVATIONAL COMPARATIVE STUDY USING ROUTINE CARE DATA. | Ruiz-Irastorza, G, medRxiv, 2020 | Full text |
| A Small-Scale Medication of Leflunomide as a Treatment of COVID-19 in an Open-Label Blank-Controlled Clinical Trial. | Hu K, Virologica Sinica, 2020 | Full text |
| Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study. | Abolghasemi H, Transfusion and apheresis science, 2020 | Full text |
| Tocilizumab for patients with severe COVID-19: a retrospective, multi-centre study. | Tomasiewicz K, Expert review of anti-infective therapy, 2020 | Full text |
| Prophylaxis with tetracyclines in ARDS: Potential therapy for COVID-19-induced ARDS? | Byrne, J. D, medRxiv, 2020 | Full text |
| Resveratrol and Copper for treatment of severe COVID-19: an observational study (RESCU 002) | Mittra, I, medRxiv, 2020 | Full text |
| PLEXIT - Therapeutic plasma exchange (TPE) for Covid-19 cytokine release storm (CRS), a retrospective propensity matched control study | kamran, s. m, medRxiv, 2020 | Full text |
| Efficacy and tolerability of bevacizumab in patients with severe Covid -19 | Pang, J, medRxiv, 2020 | Full text |
| Use of a humanized anti-CD6 monoclonal antibody (itolizumab) in elderly patients with moderate COVID-19 | Ramos-Suzarte, M, medRxiv, 2020 | Full text |
| Nicotine-replacement therapy, as a surrogate of smoking, and the risk of hospitalization with Covid-19 and all-cause mortality: a nationwide, observational cohort study in France | Zureik, M, medRxiv, 2020 | Full text |
| Tocilizumab shortens time on mechanical ventilation and length of hospital stay in patients with severe COVID-19: a retrospective cohort study. | Eimer, J, medRxiv, 2020 | Full text |
| Corticosteroid Use in Severely Hypoxemic COVID-19 Patients: An Observational Cohort Analysis of Dosing Patterns and Outcomes in the Early Phase of the Pandemic | Rahman, O, medRxiv, 2020 | Full text |
| Safety, tolerability, and clinical outcomes of hydroxychloroquine for hospitalized patients with coronavirus 2019 disease. | Satlin MJ, PloS one, 2020 | Full text |
| Interleukin-6 receptor blocking with intravenous tocilizumab in COVID-19 severe acute respiratory distress syndrome: A retrospective case-control survival analysis of 128 patients. | Canziani LM, Journal of autoimmunity, 2020 | Full text |
| Ribavirin Therapy For Severe COVID-19: A Retrospective Cohort Study. | Song T, International journal of antimicrobial agents, 2020 | Full text |
| Clinical Characteristics and Predictors of Disease Progression in Severe Patients with COVID-19 Infection in Jiangsu Province, China: A Descriptive Study. | Huang M, The American journal of the medical sciences, 2020 | Full text |
| Safety and efficacy of tocilizumab in the treatment of severe acute respiratory syndrome coronavirus-2 pneumonia: A retrospective cohort study. | Patel A, Indian journal of medical microbiology, 2020 | Full text |
| Clinical Use of Short-Course and Low-Dose Corticosteroids in Patients With Non-severe COVID-19 During Pneumonia Progression. | Hu Z, Frontiers in public health, 2020 | Full text |
| The Association of Interleukin-6 value, Interleukin inhibitors and Outcomes of Patients with COVID-19 in New York City. | Maeda T, Journal of medical virology, 2020 | Full text |
| [Steroid pulse -therapy in patients With coronAvirus Pneumonia (COVID-19), sYstemic inFlammation And Risk of vEnous thRombosis and thromboembolism (WAYFARER Study)]. | Mareev VY, Kardiologiia, 2020 | Full text |
| Famotidine Use is Associated with Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study | Daniel E. Freedberg, medRxiv, 2020 | Full text |
| Safety and potential efficacy of cyclooxygenase-2 inhibitors in coronavirus disease 2019. | Ong SWX, Clinical & translational immunology, 2020 | Full text |
| Appropriate use of Tocilizumab in COVID-19 Infection. | Keske ?, International journal of infectious diseases, 2020 | Full text |
| Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome. | Scarsi M, Annals of the rheumatic diseases, 2020 | Full text |
| The characteristics and outcomes of 681 severe cases with COVID-19 in China. | Chen FF, Journal of critical care, 2020 | Full text |
| Clinical efficacy of glucocorticoid on the treatment of patients with COVID-19 pneumonia: A single-center experience. | Hu Y, Biomedicine & pharmacotherapy, 2020 | Full text |
| BCG vaccination early in life does not improve COVID-19 outcome of elderly populations, based on nationally reported data. | Wassenaar TM, Letters in applied microbiology, 2020 | Full text |
| A retrospective evaluation on the efficacy of Lopinavir/ritonavir and chloroquine to treat non-severe COVID-19 patients. | Gao G, Journal of acquired immune deficiency syndromes, 2020 | Full text |
| Impact of tocilizumab administration on mortality in severe COVID-19 | Tsai, A, medRxiv, 2020 | Full text |
| Therapeutic effectiveness of interferon alpha 2b treatment for COVID-19 patient recovery | Pereda, R, medRxiv, 2020 | Full text |
| COVIDOSE: Low-dose tocilizumab in the treatment of Covid-19. | Strohbehn GW, medRxiv, 2020 | Full text |
| Corticosteroid, oseltamivir, and delayed admission are independent risk factors for prolonged viral shedding in patients with Coronavirus Disease 2019. | Hu F, The clinical respiratory journal, 2020 | Full text |
| Early Hydroxychloroquine Administration for Rapid Severe Acute Respiratory Syndrome Coronavirus 2 Eradication. | Infection & chemotherapy | Full text |
| nImpact of medical care including anti-infective agents use on the prognosis of COVID-19 hospitalized patients over time. | International journal of antimicrobial agents | Full text |
| Corticosteroid therapy for patients with severe novel Coronavirus disease 2019. | European review for medical and pharmacological sciences | Full text |
| Morning vs. evening administration of antiviral therapy in COVID-19 patients. A preliminary retrospective study in Ferrara, Italy. | European review for medical and pharmacological sciences | Full text |
| Tocilizumab for treatment of patients with severe COVID-19: A retrospective cohort study. | EClinicalMedicine | Full text |
| Hydroxychloroquine use in Hospitalized Patients with COVID-19: An observational matched cohort study. | Journal of global antimicrobial resistance | Full text |
| Therapeutic plasma exchange in adult critically ill patients with life-threatening SARS-CoV-2 disease: A pilot study. | Journal of critical care | Full text |
| Low-Dose Subcutaneous Tocilizumab to Prevent Disease Progression in Patients with Moderate COVID-19 Pneumonia and Hyperinflammation. | International journal of infectious diseases | Full text |
| Early Identification of COVID-19 Cytokine Storm and Treatment with Anakinra or Tocilizumab. | International journal of infectious diseases | Full text |
| Effects of Hydroxychloroquine on Covid-19 in Intensive Care Unit Patients: Preliminary Results. | International journal of antimicrobial agents | Full text |
| Early administration of lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of SARS-CoV-2 infection: a retrospective cohort study. | Journal of medical virology | Full text |
| Hydroxychloroquine versus lopinavir/ritonavir in severe COVID-19 patients : Results from a real-life patient cohort. | Wiener klinische Wochenschrift | Full text |
| Clinical Outcomes Associated with Methylprednisolone in Mechanically Ventilated Patients with COVID-19. | Clinical infectious diseases | Full text |
| Adjunctive Corticosteroids for COVID-19: A Retrospective Cohort Study | medRxiv | Full text |
| Associations between mask-wearing, handwashing, and social distancing practices and risk of COVID-19 infection in public: a case-control study in Thailand | Doung-ngern, P, medRxiv, 2020 | Full text |
| Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience | Joyner, M. J, medRxiv, 2020 | Full text |
| Tocilizumab in hospitalized patients with COVID-19: Clinical outcomes, inflammatory marker kinetics, safety, and a review of the literature | Hill, J. A, medRxiv, 2020 | Full text |
| Hydroxychloroquine treatment in COVID-19: a descriptive observational analysis of 30 cases from a single center in Wuhan, China. | Xue H, Journal of medical virology, 2020 | Full text |
| SARS-CoV-2 Neutralizing Antibody Titers in Convalescent Plasma and Recipients in New Mexico: An Open Treatment Study in COVID-19 Patients. | Bradfute SB, The Journal of infectious diseases - Volume , Issue , pp. - published 2020-08-11, 2020 | Full text |
| Late Onset Infectious Complications and Safety of Tocilizumab in the Management of COVID-19. | Pettit NN, Journal of medical virology, 2020 | Full text |
| Efficacy of hydroxychloroquine and tocilizumab in patients with COVID-19: A single-center retrospective chart review. | Roomi S, Journal of medical Internet research , 2020 | Full text |
| Impact of implementation of an individualised thromboprophylaxis protocol in critically ill ICU patients with COVID-19: A longitudinal controlled before-after study. | Stessel B, Thrombosis research, 2020 | Full text |
| Hydroxychloroquine and tocilizumab therapy in COVID-19 patients-An observational study. | Ip A, PloS one, 2020 | Full text |
| Corticosteroid prevents COVID-19 progression within its therapeutic window: a multicenter, proof-of-concept,?observational?study. | Li Y, Emerging microbes & infections, 2020 | Full text |
| Oxygen-ozone (O(2)-O(3)) immunoceutical therapy for patients with COVID-19. Preliminary evidence reported. | Franzini M, International immunopharmacology , 2020 | Full text |
| Thymosin ?1 therapy in critically ill patients with COVID-19: A multicenter?retrospective cohort?study. | Wu M, International immunopharmacology , 2020 | Full text |
| Treatment of COVID-19 Patients with Convalescent Plasma Reveals a Signal of Significantly Decreased Mortality. | Salazar E, The American journal of pathology, 2020 | Full text |
| First report of tocilizumab use in a cohort of Latin American patients hospitalized for severe COVID-19 pneumonia | Valenzuela, O, medRxiv, 2020 | Full text |
| Sixty-day mortality among 520 Italian hospitalized COVID-19 patients according to the adopted ventilatory strategy in the context of an integrated multidisciplinary clinical organization: a population-based cohort study | Potalivo, A, medRxiv, 2020 | Full text |
| Outcomes of Persons With COVID-19 in Hospitals With and Without Standard Treatment With (Hydroxy)chloroquine | Peters, E. J, medRxiv, 2020 | Full text |
We recognize that our process might not be perfect. Please contact us if you identify an error